Caladrius Biosciences Completes Enrollment in Phase 2 ESCaPE-CMD Trial for Coronary Microvascular Dysfunction
Caladrius Biosciences, Inc. (CLBS)
Last caladrius biosciences, inc. earnings: 11/6 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
caladrius.com/investors/overview
Company Research
Source: GlobeNewswire
BASKING RIDGE, N.J., June 04, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced today the completion of enrollment and dosing in the Phase 2 ESCaPE-CMD study for CLBS16 (formerly known as CLBS14-CMD) in patients with coronary microvascular dysfunction (“CMD”). The Company expects to announce topline results shortly after the last patient completes follow up at the end of 2019. “The completion of enrollment and dosing for this important study marks the first of several clinical milestones Caladrius expects to announce during the next 12-18 months and we look forward to sharing the results of the ESCaPE-CMD study after the last patient completes the 6 month follow up at the end of this year,” said Douglas W. Losordo, MD, FACC, FAHA, Executive Vice President, Global Head o
Show less
Read more
Impact Snapshot
Event Time:
CLBS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLBS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLBS alerts
High impacting Caladrius Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics